Arca
Skip to content
Tools
Tools

TNF: Tumor necrosis factor

Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR.

  • Drugs that act on it: 15
  • Approved: 5
  • In phases 1 to 3: 10
  • Sponsors: 10

Who is on it, and how far along

Every drug ChEMBL records acting on TNF, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 9
  • Protein or peptide 4
  • Other 2

Approved5

  • Adalimumab
  • Infliximab
  • Etanercept
  • Golimumab
  • Certolizumab pegol

Phase 33

  • Lenercept
  • Nerelimomab
  • Onercept

Phase 27

  • ABBV-3373
  • Afelimomab
  • AZ9773
  • Ozoralizumab
  • Pegsunercept
  • Placulumab
  • Remtolumab

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Arana Therapeutics Ltd17%
    • Mirador Therapeutics, Inc.17%
    • Sorrento Therapeutics, Inc.17%
    • Surmount Services, Inc.17%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 14 of 15 act as: TNF-alpha inhibitor; the rest name their own mechanism.
    AdalimumabBoxed warningApprovedSurmount Services, Inc.AntibodyInhibitor111
    InfliximabBoxed warningApprovedMirador Therapeutics, Inc.AntibodyInhibitor99
    EtanerceptBoxed warningApprovedSorrento Therapeutics, Inc.Protein or peptideInhibitor32
    GolimumabBoxed warningApprovedBristol-Myers SquibbAntibodyInhibitor21
    Certolizumab pegolBoxed warningApprovedUCBAntibodyInhibitor15
    LenerceptPhase 3—Protein or peptideInhibitor0
    NerelimomabPhase 3—AntibodyInhibitor0
    OnerceptPhase 3Merck KGaAProtein or peptideInhibitor0
    ABBV-3373Phase 2AbbVieOtherBinding agentTNF-alpha binding agent0
    AfelimomabPhase 2—AntibodyInhibitor0
    AZ9773Phase 2—OtherInhibitor0
    OzoralizumabPhase 2SanofiAntibodyInhibitor0
    PegsunerceptPhase 2AmgenProtein or peptideInhibitor0
    PlaculumabPhase 2Arana Therapeutics LtdAntibodyInhibitor0
    RemtolumabPhase 2AbbVieAntibodyInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 31 in all, from ClinicalTrials.gov.
    Non-Invasive Biomarker Monitoring in UC on BiologicsInfliximab—Not yet recruitingUniversity Hospitals Coventry and Warwickshire NHS TrustNov 5, 2026
    Efficacy and Safety of Adalimumab for the Treatment of Ocular InflammationAdalimumabNot applicableNot yet recruitingSamsung Medical CenterNov 3, 2026
    Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic ArthritisAdalimumab, Etanercept, GolimumabPhase 4Not yet recruitingOslo University HospitalOct 29, 2026
    Precision Depression Adalimumab TrialAdalimumabPhase 2RecruitingDaniel MoriaritySep 29, 2026
    Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of BimekizumabAdalimumabPhase 3Not yet recruitingUniversity Hospital, RouenSep 23, 2026
    Conventional vs Biologic Therapy in Pediatric IBDAdalimumab, Infliximab—Not yet recruitingAssiut UniversitySep 14, 2026
    A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the ColonAdalimumabPhase 1RecruitingSurmount Services, Inc.Aug 26, 2026
    A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy ParticipantsInfliximabPhase 1RecruitingMirador Therapeutics, Inc.Aug 20, 2026
    An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory UveitisAdalimumabPhase 4Active, not recruitingTianjin Medical UniversityAug 19, 2026
    The Efficacy of Lactobacillous Probiotic and Trace Elements in the Management of Ulcerative Colitis Patients the Patients Will be Recruited From Outpatient Clinic of Inflammatory Bowel Disease (IBD) of the National Hepatology and Tropical Medicine Research Institute NHTMRI, Cairo, EgyptInfliximabPhase 4RecruitingNational Hepatology & Tropical Medicine Research InstituteAug 11, 2026
    The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung CancerAdalimumabPhase 2Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.Jul 15, 2026
    Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's DiseaseInfliximab—RecruitingShanghai 10th People's HospitalJul 10, 2026
    Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs PlaceboGolimumabPhase 2Not yet recruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Jul 6, 2026
    Infliximab for Immune Checkpoint Inhibitor Associated AKIInfliximabPhase 4RecruitingMassachusetts General HospitalJul 6, 2026
    Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye DiseaseInfliximabPhase 2Not yet recruitingInstituto de Oftalmología Fundación Conde de ValencianaJun 26, 2026
    Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaInfliximabPhase 2RecruitingNaresh BummaJun 18, 2026
    Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel DiseaseCertolizumab pegol, Golimumab—RecruitingShmuel Kivity, MDJun 12, 2026
    Ex Vivo Perfusion of Gene-Edited Porcine Livers in Patients With Severe Hepatic FailureEtanerceptEarly phase 1Active, not recruitingXijing HospitalApr 9, 2026
    Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper EgyptGolimumab—Not yet recruitingAssiut UniversityMar 27, 2026
    Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained RemissionCertolizumab pegolNot applicableRecruitingMarmara UniversityMar 25, 2026
    Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic ArthritisEtanerceptPhase 3Enrolling by invitationUniversity of Child Health Sciences and Children's Hospital, LahoreFeb 4, 2026
    Utilization of a Microdevice for Psoriasis and Atopic DermatitisCertolizumab pegol, EtanerceptPhase 4Not yet recruitingUniversity of California, San FranciscoJan 20, 2026
    Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDEtanerceptNot applicableRecruitingFirst Affiliated Hospital of Zhejiang UniversitySep 22, 2025
    A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular BiomarkersCertolizumab pegol, Etanercept, GolimumabPhase 4RecruitingTaichung Veterans General HospitalSep 2, 2025
    Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyCertolizumab pegol, Etanercept, GolimumabPhase 2RecruitingNYU Langone HealthAug 24, 2025
    SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)Certolizumab pegol—RecruitingLeiden University Medical CenterJun 15, 2025
    Effect and Safety of Benzathine Penicillin Combined With Etanercept on SpondyloarthritisEtanerceptPhase 4RecruitingNanfang Hospital, Southern Medical UniversityNov 27, 2024
    A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their InfantsGolimumab—Active, not recruitingBristol-Myers SquibbNov 13, 2023
    Ibd CAncer and seRious Infections in France (I-CARE 2)Golimumab—RecruitingGroupe d'Etude Therapeutique des Affections Inflammatoires DigestivesOct 18, 2023
    Certolizumab in Recurrent Implantation Failure (RIF)Certolizumab pegolPhase 3RecruitingAssistance Publique - Hôpitaux de ParisJul 5, 2023
    Stand UP to Rheumatoid Arthritis (SUPRA)Certolizumab pegolNot applicableRecruitingMarie Hudson, MDMar 31, 2022

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Crohn disease
    0.62
    Psoriasis vulgaris
    0.61
    Arthritic joint disease
    0.57
    Immune system disorder
    0.56

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1825, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P01375, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.